An Adaptive Multicentre, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Safety, PK and PD/Efficacy of RLX030 in Women With Pre-eclampsia

Trial Profile

An Adaptive Multicentre, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Safety, PK and PD/Efficacy of RLX030 in Women With Pre-eclampsia

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2015

At a glance

  • Drugs Serelaxin (Primary)
  • Indications Preeclampsia
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 14 Jul 2014 Planned End Date changed from 1 Apr 2017 to 1 Apr 2014 as reported by ClinicalTrials.gov.
    • 14 Jul 2014 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2014 as reported by ClinicalTrials.gov.
    • 14 Jul 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top